product name Leucovorin Calcium
Description: Leucovorin is a derivative of folic acid, which can be used to increase levels of folic acid under conditions favoring folic acid inhibition. Leucovorin administration increases the level of reduced folates in tissues, which promotes the inhibition of thymidylate synthase in two murine colon tumors. Leucovorin, Gemcitabine, Oxaliplatin, and 5-fluorouracil is a powerful antitumor and immunomodulating regimen that can make the tumor cells a suitable means to induce an Ag-specific CTL response.
References: Cancer Res. 1992 Sep 15;52(18):4922-8; J Immunol. 2005 Jul 15;175(2):820-8; Clin Cancer Res. 2000 Sep;6(9):3646-56; Int J Cancer. 1998 Mar 16;75(6):873-7.
601.58
Formula
C21H25CaN7O7.5H2O
CAS No.
6035-45-6
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: <1 mg/mL
Water: 40 mg/mL (66.5 mM)
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
Folinic acid
other peoduct :
| In Vitro |
In vitro activity: Leucovorin administration increases the level of reduced folates in tissues, which promotes the inhibition of thymidylate synthase in two murine colon tumors. Leucovorin, Gemcitabine, Oxaliplatin, and 5-fluorouracil is a powerful antitumor and immunomodulating regimen that can make the tumor cells a suitable means to induce an Ag-specific CTL response. Leucovorin (20 mM) increases the cytotoxicity in all three replicate experiments in 10 of the 11 human colorectal carcinoma cell lines. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells. Leucovorin (LV) is a reduced folate cofactor that competes with RTX for transport and polyglutamation in both tumor and normal tissues and thus has potential as a rescue agent. Leucovorin reverses the growth-inhibitory, and potentially cytotoxic, effects of RTX on populations of viable cells. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Leucovorin (200 mg/kg), which is given after the onset of severe weight loss and diarrhea (twice daily, days 5-7) in mice, prevents further weight loss and induces earlier recovery. Leucovorin (100 or 200 mg/kg; twice daily on days 4-6) reduces the RTX concentration in the liver 2-4-fold on days 7, 9, and 11 compared with controls. Leucovorin/5-FU and Gastrimmune (200 mg/mL) combinations (12.5 and 20 mg/kg) increase the therapeutic effects on the in vivo growth of DHDK12 tumors when compared to the agents given singly. |
| Animal model | |
| Formulation & Dosage | |
| References | Cancer Res. 1992 Sep 15;52(18):4922-8; J Immunol. 2005 Jul 15;175(2):820-8; Clin Cancer Res. 2000 Sep;6(9):3646-56; Int J Cancer. 1998 Mar 16;75(6):873-7. |
